8-K
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 19, 2024
LIXTE
BIOTECHNOLOGY HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
| delaware | 001-39717 | 20-2903526 |
|---|---|---|
| (State<br> or other jurisdiction<br><br> <br>of<br> incorporation) | (Commission<br><br> <br>File<br> Number) | (I.R.S.<br> Employer<br><br> <br>Identification<br> Number) |
680 East Colorado Boulevard, Suite 180
Pasadena, California 91101
(Address of principal executive offices)
(631) 830-7092
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written<br> communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title<br> of Each Class | Trading<br> Symbol(s) | Name<br> of each exchange on which registered |
|---|---|---|
| Common<br> Stock, par value $0.0001 per share | LIXT | The<br> Nasdaq Stock Market LLC |
| Warrants<br> to Purchase Common Stock, par value $0.0001 per share | LIXTW | The<br> Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
On December 19, 2024, the Company held its Annual Meeting . The matters voted upon were:
Proposal1: The election of five director nominees to the Company’s Board of Directors to serve for a one-year term expiring at the 2025 annual meeting of stockholders.
Proposal2: To ratify the appointment of Weinberg & Company, P.A. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.
Proposal3: To approve, on an advisory basis, the compensation of the Company’s named executive officers.
The results of the voting were as follows:
Proposal1 (election of directors):
Each of the director nominees to the Company’s Board of Directors was elected as follows:
| Nominee | Votes For | Votes Withheld | Broker Non-Votes |
|---|---|---|---|
| Dr. Stephen Forman | 653,305 | 80,078 | 670,623 |
| Dr. Yun Yen | 691,844 | 41,615 | 670,547 |
| Regina Brown | 691,346 | 42,113 | 670,547 |
| Dr. René Bernards | 691,863 | 41,596 | 670,547 |
| Bas van der Baan | 678,222 | 55,161 | 670,623 |
Proposal2 (appointment of accounting firm):
| Votes For | Votes Against | Abstain | Broker Non-Votes |
|---|---|---|---|
| 1,329,980 | 56,472 | 17,554 | 0 |
Proposal3 (compensation of officers):
| Votes For | Votes Against | Abstain | Broker Non-Votes |
|---|---|---|---|
| 672,202 | 40,248 | 21,009 | 670,547 |
| 2 |
| --- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date:<br> December 20, 2024 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | |
|---|---|---|
| (Registrant) | ||
| By: | /s/ BASTIAAN VAN DER BAAN | |
| Bastiaan<br> van der Baan | ||
| Chief Executive Officer |
| 3 |
| --- |